Latest news with #Hemanext
Associated Press
21-05-2025
- Business
- Associated Press
Hemanext Welcomes New Member to Board of Directors
Lexington, MA May 21, 2025 --( )-- Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, announces the appointment of Geoff Crouse, an esteemed professional with over 25 years of leadership in the life sciences sector, to its Board of Directors. Geoff Crouse joins the visionary leadership team guiding Hemanext's mission to elevate the standard of care for patients who depend on transfusions. Geoff serves as CEO and Board Member of Candela Medical, one of the world's largest global medical aesthetic device companies, since 2017, overseeing the company's global operations in the US, Europe, China and Japan. Additionally, he has previously held key executive roles including Chief Executive Officer (CEO) of Cord Blood Registry and Chief Operating Officer (COO) of Immucor, as well as senior positions at Millipore and Roche Diagnostics. At Cord Blood Registry, he completed the acquisition of the Company in partnership with GTCR and ultimately selling it to AMAG Pharmaceuticals in a transaction valued at over $700M. He also served on the Board of Invitae, supporting its growth from early-stage financing to a successful Initial Public Offering (IPO). Geoff holds a BA in English from Boston College and both an MBA and MPH from the University of California, Berkeley. 'We are delighted to welcome Geoff to Hemanext's Board of Directors,' Andrew Dunham, CEO of Hemanext stated, 'His depth of experience and forward-thinking perspectives will be instrumental as we advance our mission and drive innovation. We look forward to his contributions as we enter this next phase of growth.' About Hemanext Hemanext is a privately held medical technology company based in Lexington, MA that is dedicated to improving the quality, safety, efficacy, and cost of transfusion therapy. The company's research and development efforts focus on the study of hypoxically stored red blood cells (RBCs). The company's aim is to significantly improve the quality of stored RBCs worldwide. Visit to learn more about the Company. About Hemanext ONE HEMANEXT ONE has been granted marketing authorization for commercial distribution via the De Novo process by the U.S. Food & Drug Administration. It is intended to process and store CP2D/AS-3 Red Blood Cells, Leukocytes Reduced (LR RBC) that have been prepared within the standard 8-hour hold time. Processing of Red Blood Cells processed with the HEMANEXT ONE system must be initiated within 8 hours of collection and completed within 12 hours of collection. The Red Blood Cells must be processed at room temperature (20-26°C). The HEMANEXT ONE system limits O2 and CO2 levels in the storage environment. Red Blood Cells Leukocytes Reduced, O2/ CO2 Reduced may be stored for up to 42 days at 1-6°C. HEMANEXT ONE is used for volumes no greater than 350 mL of LR RBC. In Europe, HEMANEXT ONE is CE marked, which allows its commercial distribution within the market of the European Economic Area (EEA). The HEMANEXT ONE RBC Processing and Storage system limits oxygen, the fuel for oxidative damage, providing a higher quality blood product (1,2,3). It has the potential to benefit all patients requiring transfusion for chronic conditions, such as thalassemia (4), sickle cell disease (SCD)(5), and myelodysplastic syndromes (MDS)(6), as well as those in need of critical transfusions during acute bleeding in surgery, trauma and other medical procedures (7). HEMANEXT ONE creates hypoxic RBCs, RBCs that have been processed to reduce oxygen and carbon dioxide content of RBCs and to maintain these levels throughout storage up to 42 days (3). Hypoxic RBCs have demonstrated positive impacts on multiple in vitro metrics of RBC quality in preclinical studies (8,9). Clinical studies are underway to determine the impact of hypoxic RBCs on patient outcomes and estimate potential cost savings from expected improvements in care and reductions in transfusion volumes (10). Hemanext Media Contact Robert Haime Vice President, Commercial [email protected] (781) 301-7474 References 1. Rabcuka J, Blonski S, Meli A, et al. Metabolic reprogramming under hypoxic storage preserves faster oxygen unloading from stored red blood cells. Blood Adv. 2022;6(18):5415-5428. doi: 10.1182/bloodadvances.2022007774 2. Reisz JA, Wither MJ et al. Oxidative modifications of glyceraldehyde 3-phosphate dehydrogenase regulate metabolic reprogramming of stored red blood cells. 2016;128(12): e32-42. 3. HEMANEXT ONE® (Blood container set used to process and store CP2D/AS-3 Red Blood Cells, Leukocytes Reduced, and O2/CO2 Reduced) [US Instructions for Use]. Lexington, MA: Hemanext Inc. 4. Farmakis D, Porter J, Taher A, et al. 2021 Thalassemia International Federation Guidelines for the management of transfusion-dependent thalassemia. 2022;6:8. 5. Chou S, Alsawas M, Fasano R, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020;4:2. 6. Germing U, Oliva E, Hiwase D, and Almeida A. Treatment of anemia in transfusion-dependent and non-transfusion-dependent lower-risk MDS: current and emerging strategies. 2019;3(6). doi: 10.1097/HS9.0000000000000314 7. American College of Surgeons. ACS TQIP massive transfusion in trauma guidelines. ACS TQIP. 2014; 8. Yoshida T, Blair A, D'Alessandro A, et al. Enhancing uniformity and overall quality of red cell concentrate with anaerobic storage. Blood Transfus. 2017;15(2):172-81. 9. Yoshida T, McMahon E, Croxon H, et al. The oxygen saturation of red blood cell concentrates: The basis for a novel index of red cell oxidative stress. Transfusion. 2022;62(1):183-193. doi: 10.1111/trf.16715. 10. Reikvam H, Hetland G, Ezligini F, et al. Safety of hypoxic red blood cell administration in patients with transfusion-dependent hematological malignancies: An interim analysis. Transfus Apher Sci. 2023; doi: 10.1016/ Contact Information: Hemanext Robert Haime, Vice President, Commercial (781) 301-7474 Contact via Email Read the full story here: Hemanext Welcomes New Member to Board of Directors Press Release Distributed by
Associated Press
06-05-2025
- Business
- Associated Press
Hemanext Expands Board of Directors with Two New Members
Lexington, PA May 05, 2025 --( )-- Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, announces the appointment of two distinguished professionals to its Board of Directors. Joe Grogan and Phil Pead join the visionary leaders that are steering Hemanext's path to improving the standard of care for patients who rely on transfusions. Joe Grogan is a healthcare expert with over two decades of experience in both the private sector and government, particularly in Washington, DC. He began his career as Executive Director of the Presidential Advisory Council on HIV and AIDS during the George W. Bush administration and later worked at the Food and Drug Administration (FDA). In the private sector, he advised Wall Street investors and worked for Amgen and Gilead Sciences, where he founded Gilead's DC office and led federal efforts during three major drug launches. Joe also served at the Office of Management and Budget, managing over $1.3 trillion in healthcare spending and drafting health sections of three Presidential Budgets. He later served as Domestic Policy Advisor in the West Wing, leading healthcare policy development and contributing to the President's Covid Task Force. Joe founded Fire Arrow to guide innovators through the complexities of Washington, DC, and help deliver products to those in need. Phil M Pead is a seasoned technology executive and board member with over 40 years of leadership experience in the Healthcare IT and software industries. He has served as CEO of Per-Se Technologies, Eclipsys, and Progress Software, leading major turnarounds, mergers, and acquisitions. He currently sits on the boards of Modernizing Medicine and WebPT and has held past roles with Change Healthcare and Allscripts. A Harvard Business Review case study highlights his leadership at Per-Se, and he has taught the 'Managing in Adversity' class at MIT Sloan Business School for four years. He is also a national board member and Secretary for the Posse Foundation. Andrew Dunham, CEO of Hemanext, warmly welcomes the addition to Hemanext's Board of Directors, 'We're thrilled to welcome Joe and Phil to our Board of Directors. Their expertise and vision will be invaluable as we continue to grow and innovate. We're excited for the journey ahead with such strong additions to our leadership team.' About Hemanext Hemanext is a privately held medical technology company based in Lexington, MA, that is dedicated to improving the quality, safety, efficacy, and cost of transfusion therapy. The company's research and development efforts focus on the study of hypoxically stored Red Blood Cells (RBCs). The company's aim is to significantly improve the quality of stored RBCs worldwide. Visit to learn more about the Company. About Hemanext ONE Hemanext ONE has been granted marketing authorization for commercial distribution via the De Novo process by the U.S. Food & Drug Administration. It is intended to process and store CP2D/AS-3 Red Blood Cells, Leukocytes Reduced (LR RBC) that have been prepared within the standard 8-hour hold time. Processing of Red Blood Cells processed with the Hemanext ONE system must be initiated within 8 hours of collection and completed within 12 hours of collection. The Red Blood Cells must be processed at room temperature (20-26°C). The Hemanext ONE system limits O2 and CO2 levels in the storage environment. Red Blood Cells Leukocytes Reduced, O2/ CO2 Reduced may be stored for up to 42 days at 1-6°C. Hemanext ONE is used for volumes no greater than 350 mL of LR RBC. In Europe, Hemanext ONE is CE marked, which allows its commercial distribution within the market of the European Economic Area (EEA). The Hemanext ONE RBC Processing and Storage system limits oxygen, the fuel for oxidative damage, providing a higher quality blood product (1,2,3). It has the potential to benefit all patients requiring transfusion for chronic conditions, such as thalassemia (4), sickle cell disease (SCD) (5), and myelodysplastic syndromes (MDS) (6), as well as those in need of critical transfusions during acute bleeding in surgery, trauma and other medical procedures (7). Hemanext ONE creates hypoxic RBCs, RBCs that have been processed to reduce oxygen and carbon dioxide content of RBCs and to maintain these levels throughout storage up to 42 days (3). Hypoxic RBCs have demonstrated positive impacts on multiple in vitro metrics of RBC quality in preclinical studies (8,9). Clinical studies are underway to determine the impact of hypoxic RBCs on patient outcomes and estimate potential cost savings from expected improvements in care and reductions in transfusion volumes (10). Hemanext Media Contact Robert Haime Vice President, Commercial [email protected] (781) 301-7474 References 1. Rabcuka J, Blonski S, Meli A, et al. Metabolic reprogramming under hypoxic storage preserves faster oxygen unloading from stored red blood cells. Blood Adv. 2022;6(18):5415-5428. doi: 10.1182/bloodadvances.2022007774 2. Reisz JA, Wither MJ et al. Oxidative modifications of glyceraldehyde 3-phosphate dehydrogenase regulate metabolic reprogramming of stored red blood cells. 2016;128(12): e32-42. 3. Hemanext ONE® (Blood container set used to process and store CP2D/AS-3 Red Blood Cells, Leukocytes Reduced, and O2/CO2 Reduced) [US Instructions for Use]. Lexington, MA: Hemanext Inc. 4. Farmakis D, Porter J, Taher A, et al. 2021 Thalassemia International Federation Guidelines for the management of transfusion-dependent thalassemia. 2022;6:8. 5. Chou S, Alsawas M, Fasano R, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020;4:2. 6. Germing U, Oliva E, Hiwase D, and Almeida A. Treatment of anemia in transfusion-dependent and non-transfusion-dependent lower-risk MDS: current and emerging strategies. 2019;3(6). doi: 10.1097/HS9.0000000000000314 7. American College of Surgeons. ACS TQIP massive transfusion in trauma guidelines. ACS TQIP. 2014; 8. Yoshida T, Blair A, D'Alessandro A, et al. Enhancing uniformity and overall quality of red cell concentrate with anaerobic storage. Blood Transfus. 2017;15(2):172-81. 9. Yoshida T, McMahon E, Croxon H, et al. The oxygen saturation of red blood cell concentrates: The basis for a novel index of red cell oxidative stress. Transfusion. 2022;62(1):183-193. doi: 10.1111/trf.16715. 10. Reikvam H, Hetland G, Ezligini F, et al. Safety of hypoxic red blood cell administration in patients with transfusion-dependent hematological malignancies: An interim analysis. Transfus Apher Sci. 2023; doi: 10.1016/ Contact Information: Hemanext Robert Haime, Vice President, Commercial (781) 301-7474 Contact via Email Read the full story here: Hemanext Expands Board of Directors with Two New Members Press Release Distributed by
Associated Press
27-01-2025
- Business
- Associated Press
Hemanext Announces Close of Series B-2 Equity Funding Round
Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, announces close of series B-2 equity fundraising round. The B-2 fundraising was launched in May 2024 to raise $16-20 million and was completed in October 2024, raising just over $20 million at a pre-money valuation of $115 million or $0.25 per share. Hemanext has recently reached the financial close of the round, with support coming from both existing and new investors in nearly equal measure. Hemanext expects the $20 million raised to support achievement of several real-world commercial objectives through June 2025, specifically: 1. Achieve successful implementation in the United States (US) and Europe across a variety of blood establishment categories. Progress towards this goal has already been made in the US, Greece and Norway. 2. Gather real world evidence on the performance and benefits of Hemanext ONE® across various hospitals, therapeutic areas, and countries, involving thousands of transfusions. 3. Establish pricing for a broader commercial launch in the US and EU after June 2025, supported by contractual outcomes and the HCPCS reimbursement pricing in the US. Delivering effective performance in the second half of 2025 (H2) for customers currently working to implement Hemanext ONE is projected to result in more than $10 million in sales from this group in 2026. Andrew Dunham, Chief Executive Officer of Hemanext, expressed his enthusiasm for the conclusion of the B-2 fundraising round, stating, 'We are thrilled to have reached our $20 million goal in this challenging funding environment for early commercial phase medical device companies. On behalf of everyone at Hemanext, we extend our gratitude to our existing investors for their ongoing trust and support, and we warmly welcome our new investors as we work together to transform transfusion.' About Hemanext Hemanext is a privately held medical technology company based in Lexington, MA that is dedicated to improving the quality, safety, efficacy, and cost of transfusion therapy. The company's research and development efforts focus on the study of hypoxically stored RBCs. The company's aim is to significantly improve the quality of stored RBCs worldwide. Visit to learn more about the Company. About Hemanext ONE Hemanext ONE has been granted marketing authorization for commercial distribution via the De Novo process by the U.S. Food & Drug Administration. It is intended to process and store CP2D/AS-3 Red Blood Cells, Leukocytes Reduced (LR RBC) that have been prepared within the standard 8-hour hold time. Processing of Red Blood Cells processed with the Hemanext ONE system must be initiated within 8 hours of collection and completed within 12 hours of collection. The Red Blood Cells must be processed at room temperature (20-26°C). The Hemanext ONE system limits O2 and CO2 levels in the storage environment. Red Blood Cells Leukocytes Reduced, O2/ CO2 Reduced may be stored for up to 42 days at 1-6°C. Hemanext ONE is used for volumes no greater than 350 mL of LR RBC. In Europe, Hemanext ONE is CE marked, which allows its commercial distribution within the market of the European Economic Area (EEA). The Hemanext ONE RBC Processing and Storage system limits oxygen, the fuel for oxidative damage, providing a higher quality blood product(1,2,3). It has the potential to benefit all patients requiring transfusion for chronic conditions, such as thalassemia(4), sickle cell disease (SCD)(5), and myelodysplastic syndromes (MDS)(6), as well as those in need of critical transfusions during acute bleeding in surgery, trauma and other medical procedures(7). Hemanext ONE creates hypoxic RBCs, RBCs that have been processed to reduce oxygen and carbon dioxide content of RBCs and to maintain these levels throughout storage up to 42 days(3). Hypoxic RBCs have demonstrated positive impacts on multiple in vitro metrics of RBC quality in preclinical studies(8,9). Clinical studies are underway to determine the impact of hypoxic RBCs on patient outcomes and estimate potential cost savings from expected improvements in care and reductions in transfusion volumes(10). Hemanext Media Contact Robert Haime (781) 301-7474 References 1. Rabcuka J, Blonski S, Meli A, et al. Metabolic reprogramming under hypoxic storage preserves faster oxygen unloading from stored red blood cells. Blood Adv. 2022;6(18):5415-5428. doi: 10.1182/bloodadvances.2022007774 2. Reisz JA, Wither MJ et al. Oxidative modifications of glyceraldehyde 3-phosphate dehydrogenase regulate metabolic reprogramming of stored red blood cells. 2016;128(12): e32-42. 3. HEMANEXT ONE® (Blood container set used to process and store CP2D/AS-3 Red Blood Cells, Leukocytes Reduced, and O2/CO2 Reduced) [US Instructions for Use]. Lexington, MA: Hemanext Inc. 4. Farmakis D, Porter J, Taher A, et al. 2021 Thalassemia International Federation Guidelines for the management of transfusion-dependent thalassemia. 2022;6:8. 5. Chou S, Alsawas M, Fasano R, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020;4:2. 6. Germing U, Oliva E, Hiwase D, and Almeida A. Treatment of anemia in transfusion-dependent and non-transfusion-dependent lower-risk MDS: current and emerging strategies. 2019;3(6). doi: 10.1097/HS9.0000000000000314 7. American College of Surgeons. ACS TQIP massive transfusion in trauma guidelines. ACS TQIP. 2014; 8. Yoshida T, Blair A, D'Alessandro A, et al. Enhancing uniformity and overall quality of red cell concentrate with anaerobic storage. Blood Transfus. 2017;15(2):172-81.
